Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis

by A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova
Published 2021-07-01

EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME

by A. V. Rudakova, N. V. Lomakin
Published 2015-09-01

Comparative analysis of laparoscopic and laparotomic panhysterectomy costs in patients with early stage endometrial cancer

by O. A. Smirnova, A. M. Belyaev, I. V. Berlev, A. V. Rudakova, A. P. Karitskiy
Published 2017-05-01

ECONOMIC FEASIBILITY OF NEW CHEMOTHERAPY REGIMENS FOR TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE

by I. A. Vasilyeva, A. G. Samoylova, A. V. Rudakova, O. V. Lovacheva, K. A. Glebov, L. N. Chernousova
Published 2018-07-01

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

by S. A. Protsenko, A. V. Rudakova, F. V. Moiseyenko, E. V. Levchenko, D. E. Matsko, A. О. Ivantsov, I. I. Semenov, A. G. Ievleva, N. V. Mitushkina, A. V. Togo, A. V. Novik, E. N. Imyanitov, V. M. Moiseyenko
Published 2017-01-01

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

by A. V. Rudakova
Published 2015-09-01

PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT

by A. V. Rudakova
Published 2015-09-01

Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment

by A. V. Rudakova, E. A. Stadnik
Published 2020-04-01

COST-EFFECTIVENESS OF ANTIVIRAL THERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C (GENOTYPE 1) WITH VARIOUS SEVERITY OF FIBROSIS STAGE

by A. V. Rudakova, D. A. Gusev, A. N. Uskov, I. V. Shestakova, Yu. V. Lobzin
Published 2018-01-01

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

by A. V. Rudakova, V. A. Parfenov
Published 2015-09-01

COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS

by A. V. Rudakova
Published 2015-03-01

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION

by A. V. Rudakova
Published 2015-09-01

PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY

by A. V. Rudakova, M. S. Berezhnova
Published 2015-12-01

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION

by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Published 2017-04-01

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers

by D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Published 2016-11-01

Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism

by A. V. Rudakova
Published 2015-11-01

Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for r...

by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Published 2016-04-01

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

by A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Published 2014-11-01

PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY

by A. V. Rudakova, S. A. Protsenko, I. A. Koroleva
Published 2017-08-01

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

by A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Published 2014-11-01